Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 188Neoplasm Metastasis 152Neoplasms 141Leukemia, Myeloid, Acute 139Colorectal Neoplasms 132Breast Neoplasms 122Melanoma 96Ovarian Neoplasms 94Prostatic Neoplasms 89Recurrence 88Multiple Myeloma 84Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66Triple Negative Breast Neoplasms 58Glioma 58Stomach Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Endometrial Neoplasms 51Carcinoma, Renal Cell 49Brain Neoplasms 49Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 46Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 41Sarcoma 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Infectious Mononucleosis × 90 days × Clear all
NCT06908096 2026-05-18

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
750 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡